Therapeutics Hormonal Agents

Oral contraceptive pill for primary dysmenorrhoea

Wong CL, Farquhar C, Roberts H, Proctor M

Published October 7, 2009 Cochrane Database of Systematic Reviews
DOI 10.1002/14651858.CD002120.pub3 PMID 19821293 PMC PMC7154221

RRM Academy Synopsis

Combined birth control pills may relieve primary dysmenorrhea

Combined oral contraceptive pills may relieve period pain better than placebo, pooled trials suggest. The Cochrane review pooled randomized trials in women with primary dysmenorrhea, meaning painful periods with no pelvic cause found. The placebo comparison included 497 women. The authors call the evidence limited.

Key Findings

  • Pooled placebo-controlled trials in 497 women suggested more pain improvement with the pill (Peto odds ratio 2.01, 95% CI 1.32 to 3.08), with significant heterogeneity (I2 64%).
  • After removing studies with inadequate allocation concealment, the pooled odds ratio suggested significant benefit (2.99, 95% CI 1.76 to 5.07), and heterogeneity was no longer statistically significant (I2 0%).
  • Three studies reported adverse effects: nausea, headaches and weight gain. For any side effect, the pooled odds ratio was 1.45 (95% CI 0.71 to 2.94), with no evidence of an effect.
  • No study compared the pill with NSAIDs. Two third-generation pills, gestodene versus desogestrel, showed no evidence of a difference in pain improvement (OR 1.11, 95% CI 0.79 to 1.57).
  • One study suggested a benefit of a third-generation pill over a second-generation pill for pain improvement (OR 0.44, 95% CI 0.23 to 0.84).

Interpretation

The review pools randomized controlled trials, experiments that assign women by chance to a treatment or a comparison. Ten trials qualified out of twenty three considered. Six compared the pill with placebo and four compared different dosages of the pill. Participants had primary dysmenorrhea, and a trial was excluded when more than 20% of its women had identifiable pelvic pathology. The authors rate only three trials as methodologically sound.

RRM Context

The review says the pills suppress ovulation and lower prostaglandin from the uterine lining, so they are suppressive medications. Primary dysmenorrhea means no pelvic disease was found, yet one included trial did no pelvic exams to rule out other causes. Restorative reproductive medicine starts by looking for the cause of pain.

Abstract

Background

Dysmenorrhoea (painful menstrual cramps) is common. Combined OCPs are recommended in the management of primary dysmenorrhoea.

Objectives

To determine the effectiveness and safety of combined oral contraceptive pills for the management of primary dysmenorrhoea.

Search Strategy

We conducted electronic searches for randomised controlled trials (RCTs) in the Cochrane Menstrual Disorders and Subfertility Group Register of controlled trials CENTRAL, CCTR, MEDLINE, EMBASE, and CINAHL (first conducted in 2001, updated on 5 November 2008).

Selection Criteria

RCTs comparing all combined OCPs with other combined OCPs, placebo, no management, or management with nonsteroidal anti-inflammatories (NSAIDs) were considered.

Data Collection and Analysis

Twenty three studies were identified and ten were included. Six compared the combined OCP with placebo and four compared different dosages of combined OCP.

Main Results

One study of low dose oestrogen and four studies of medium dose oestrogen combined OCPs compared with placebo, for a combined total of 497 women, reported pain improvement. For the outcome of pain relief across the different OCPs the pooled OR suggested benefit with OCPs compared to placebo (7 RCTs: Peto OR 2.01 [95% CI 1.32, 3.08]).The Chi-squared test for heterogeneity showed there is significant heterogeneity with an I(2) statistic of 64% and a significant chi-square test (14.06, df=5, p=0.02). A sensitivity analysis removing the studies with inadequate allocation concealment suggested significant benefit of treatment with the pooled OR of 2.99 (95% CI 1.76, 5.07) and heterogeneity no longer statistically significant and I(2) statistic of 0%.Three studies reported adverse effects (Davis 2005; Hendrix 2002; GPRG 1968) The adverse effects were nausea, headaches and weight gain. Two studies reported if women experienced any side effect and no evidence of an effect was found (3 RCTs: OR = 1.45 (95% 0.71, 2.94). There was no evidence of statistical heterogeneity.There were no studies identified that compared combined OCP versus non steroidal anti-inflammatory drugsThere was no evidence of a difference for the pooled studies for 3rd generation pro gestagens (OR = 1.11 (95% CI 0.79 - 1.57)). For the 2nd generation versus 3rd generation the OR was 0.44 (95% CI 0.23-0.84) suggesting benefit of the 3rd generation OCP but this was for a single study (Winkler 2003).

Authors' Conclusions

There is limited evidence for pain improvement with the use of the OCP (both low and medium dose oestrogen) in women with dysmenorrhoea. There is no evidence of a difference between different OCP preparations.

Topics

By this author

Related research

Therapeutics › Hormonal Agents › Estrogen Preparations · General Gynecology › Pelvic Pain › Chronic Pelvic Pain · Menstrual Cycle › Cycle Disorders › Dysmenorrhea
Chooi L Wong, Cindy Farquhar, Helen Roberts, Michelle Proctor
C Wong, C Farquhar, H Roberts, M Proctor
PMID 19821293 19821293 DOI 10.1002/14651858.CD002120.pub3 10.1002/14651858.CD002120.pub3 Wong et al. 2009, Wong 2009